Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Vikas P. Sukhatme, M.D., Sc.D.


Generating an Optimal Renewable Source of Anti-Angiogenic Activity from Ovarian Cancer Cell Lines
Summer, 07/01/99 - 08/25/99
Effects of Non-Cytotoxic Doses of Taxol on Vascular Endothelial Growth Factor (VEGF) Production by Tumor Cells
Summer, 05/28/01 - 08/31/01
Circulating Factors in Patients with Systemic Inflammatory Response Syndrome(SIRS) and Sepsis
Summer, 06/19/05 - 08/27/05

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA098948 (SUKHATME, VIKAS P) Jun 1, 2003 - May 31, 2009
    Generation of Antiangiogenic Activity for Cancer Treat.
    Role: Principal Investigator
  2. R21CA097730 (SUKHATME, VIKAS P) May 15, 2003 - Apr 30, 2006
    Role: Principal Investigator
  3. R21CA082977 (SUKHATME, VIKAS P) Apr 1, 2000 - Mar 31, 2003
    Role: Principal Investigator
  4. R01CA081151 (SUKHATME, VIKAS P) Apr 1, 1999 - Jan 31, 2005
    Role: Principal Investigator
  5. R01CA077702 (SUKHATME, VIKAS P) Jan 1, 1999 - Jun 30, 2003
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19. Front Pharmacol. 2021; 12:652688. PMID: 33959018.
  2. Cicka D, Sukhatme VP. Available drugs and supplements for rapid deployment for treatment of COVID-19. J Mol Cell Biol. 2021 Jan 25. PMID: 33493301.
    Citations:    Fields:    
  3. Lowe M, Sukhatme VV, Sukhatme VP. Reducing injury response to surgery with repurposed drugs: An evolving approach to prevention of cancer metastases. Cancer. 2020 09 01; 126(17):3916-3918. PMID: 32533771.
    Citations:    Fields:    
  4. Panigrahy D, Gartung A, Yang J, Yang H, Gilligan MM, Sulciner ML, Bhasin SS, Bielenberg DR, Chang J, Schmidt BA, Piwowarski J, Fishbein A, Soler-Ferran D, Sparks MA, Staffa SJ, Sukhatme V, Hammock BD, Kieran MW, Huang S, Bhasin M, Serhan CN, Sukhatme VP. Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. J Clin Invest. 2019 06 17; 129(7):2964-2979. PMID: 31205032.
    Citations: 16     Fields:    Translation:AnimalsCells
  5. Gilligan MM, Gartung A, Sulciner ML, Norris PC, Sukhatme VP, Bielenberg DR, Huang S, Kieran MW, Serhan CN, Panigrahy D. Aspirin-triggered proresolving mediators stimulate resolution in cancer. Proc Natl Acad Sci U S A. 2019 03 26; 116(13):6292-6297. PMID: 30862734.
    Citations: 25     Fields:    Translation:AnimalsCells
  6. Sukhatme VP. Introduction: Repurposed Drugs: Teaching an Old Dog New Tricks. Cancer J. 2019 Mar/Apr; 25(2):81. PMID: 30896528.
    Citations:    Fields:    Translation:Humans
  7. Sukhatme VV, Ramalingam SS, Ahmed R, Sukhatme VP. Repurposing Food and Drug Administration-Approved Drugs to Promote Antitumor Immunity. Cancer J. 2019 Mar/Apr; 25(2):88-99. PMID: 30896530.
    Citations:    Fields:    Translation:Humans
  8. Gartung A, Yang J, Sukhatme VP, Bielenberg DR, Fernandes D, Chang J, Schmidt BA, Hwang SH, Zurakowski D, Huang S, Kieran MW, Hammock BD, Panigrahy D. Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor. Proc Natl Acad Sci U S A. 2019 01 29; 116(5):1698-1703. PMID: 30647111.
    Citations: 19     Fields:    Translation:AnimalsCells
  9. Pantziarka P, Verbaanderd C, Sukhatme V, Rica Capistrano I, Crispino S, Gyawali B, Rooman I, Van Nuffel AM, Meheus L, Sukhatme VP, Bouche G. ReDO_DB: the repurposing drugs in oncology database. Ecancermedicalscience. 2018; 12:886. PMID: 30679953.
    Citations: 18     
  10. Chang J, Bhasin SS, Bielenberg DR, Sukhatme VP, Bhasin M, Huang S, Kieran MW, Panigrahy D. Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin. FASEB J. 2019 01; 33(1):114-125. PMID: 29957058.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  11. Pantziarka P, Sukhatme V, Crispino S, Bouche G, Meheus L, Sukhatme VP. Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents. Ecancermedicalscience. 2018; 12:824. PMID: 29743944.
    Citations: 9     
  12. Sulciner ML, Serhan CN, Gilligan MM, Mudge DK, Chang J, Gartung A, Lehner KA, Bielenberg DR, Schmidt B, Dalli J, Greene ER, Gus-Brautbar Y, Piwowarski J, Mammoto T, Zurakowski D, Perretti M, Sukhatme VP, Kaipainen A, Kieran MW, Huang S, Panigrahy D. Resolvins suppress tumor growth and enhance cancer therapy. J Exp Med. 2018 01 02; 215(1):115-140. PMID: 29191914.
    Citations: 54     Fields:    Translation:HumansAnimalsCells
  13. Verbaanderd C, Maes H, Schaaf MB, Sukhatme VP, Pantziarka P, Sukhatme V, Agostinis P, Bouche G. Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents. Ecancermedicalscience. 2017; 11:781. PMID: 29225688.
    Citations: 56     
  14. Ren JG, Seth P, Ye H, Guo K, Hanai JI, Husain Z, Sukhatme VP. Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway. Sci Rep. 2017 07 03; 7(1):4537. PMID: 28674429.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  15. Matsumine H, Numakura K, Tsunoda S, Wang H, Matsumine R, Climov M, Giatsidis G, Sukhatme VP, Orgill DP. Adipose-derived aldehyde dehydrogenase-expressing cells promote dermal regenerative potential with collagen-glycosaminoglycan scaffold. Wound Repair Regen. 2017 01; 25(1):109-119. PMID: 28230922.
    Citations: 4     Fields:    Translation:AnimalsCells
  16. Jernigan FE, Hanai JI, Sukhatme VP, Sun L. Discovery of furan carboxylate derivatives as novel inhibitors of ATP-citrate lyase via virtual high-throughput screening. Bioorg Med Chem Lett. 2017 02 15; 27(4):929-935. PMID: 28129980.
    Citations: 1     Fields:    Translation:HumansCells
  17. Koerner SK, Hanai JI, Bai S, Jernigan FE, Oki M, Komaba C, Shuto E, Sukhatme VP, Sun L. Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase. Eur J Med Chem. 2017 Jan 27; 126:920-928. PMID: 27997879.
    Citations: 10     Fields:    Translation:HumansCells
  18. Pantziarka P, Bouche G, Sukhatme V, Meheus L, Rooman I, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016; 10:680. PMID: 27899953.
    Citations: 24     
  19. Tanaka T, Ikegami Y, Nakazawa H, Kuriyama N, Oki M, Hanai J, Sukhatme VP, Kaneki M. Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1a and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro. J Cell Physiol. 2017 01; 232(1):192-201. PMID: 27137755.
    Citations: 7     Fields:    Translation:HumansCells
  20. Hasegawa M, Takahashi H, Rajabi H, Alam M, Suzuki Y, Yin L, Tagde A, Maeda T, Hiraki M, Sukhatme VP, Kufe D. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. Oncotarget. 2016 Mar 15; 7(11):11756-69. PMID: 26930718.
    Citations: 37     Fields:    Translation:HumansCells
  21. Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent. Ecancermedicalscience. 2016; 10:610. PMID: 26823679.
    Citations: 22     
  22. Lemanne D, Block KI, Kressel BR, Sukhatme VP, White JD. A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea. Cureus. 2015 Dec 29; 7(12):e441. PMID: 26858922.
    Citations: 1     
  23. Varma G, Wang X, Vinogradov E, Bhatt RS, Sukhatme VP, Seth P, Lenkinski RE, Alsop DC, Grant AK. Selective spectroscopic imaging of hyperpolarized pyruvate and its metabolites using a single-echo variable phase advance method in balanced SSFP. Magn Reson Med. 2016 10; 76(4):1102-15. PMID: 26507361.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  24. Bertolini F, Sukhatme VP, Bouche G. Drug repurposing in oncology--patient and health systems opportunities. Nat Rev Clin Oncol. 2015 Dec; 12(12):732-42. PMID: 26483297.
    Citations: 79     Fields:    Translation:Humans
  25. Sukhatme V, Bouche G, Meheus L, Sukhatme VP, Pantziarka P. Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent. Ecancermedicalscience. 2015; 9:568. PMID: 26435741.
    Citations: 7     
  26. Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, Van't Veer LJ, Spellman PT, Gray JW. Erratum to: Modeling precision treatment of breast cancer. Genome Biol. 2015 May 12; 16:95. PMID: 25962591.
    Citations: 4     Fields:    
  27. Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent. Ecancermedicalscience. 2015; 9:521. PMID: 25932045.
    Citations: 21     
  28. Van Nuffel AM, Sukhatme V, Pantziarka P, Meheus L, Sukhatme VP, Bouche G. Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent. Ecancermedicalscience. 2015; 9:513. PMID: 25729426.
    Citations: 28     
  29. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy? Future Oncol. 2015; 11(2):181-4. PMID: 25591833.
    Citations: 18     Fields:    Translation:Humans
  30. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent. Ecancermedicalscience. 2014; 8:485. PMID: 25525463.
    Citations: 21     
  31. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent. Ecancermedicalscience. 2014; 8:443. PMID: 25075217.
    Citations: 26     
  32. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP, Vikas P. The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience. 2014; 8:442. PMID: 25075216.
    Citations: 63     
  33. Ren JG, Seth P, Clish CB, Lorkiewicz PK, Higashi RM, Lane AN, Fan TW, Sukhatme VP. Knockdown of malic enzyme 2 suppresses lung tumor growth, induces differentiation and impacts PI3K/AKT signaling. Sci Rep. 2014 Jun 24; 4:5414. PMID: 24957098.
    Citations: 31     Fields:    Translation:HumansAnimalsCells
  34. Xie H, Hanai J, Ren JG, Kats L, Burgess K, Bhargava P, Signoretti S, Billiard J, Duffy KJ, Grant A, Wang X, Lorkiewicz PK, Schatzman S, Bousamra M, Lane AN, Higashi RM, Fan TW, Pandolfi PP, Sukhatme VP, Seth P. Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab. 2014 May 06; 19(5):795-809. PMID: 24726384.
    Citations: 164     Fields:    Translation:HumansAnimalsCells
  35. Wegiel B, Gallo D, Csizmadia E, Harris C, Belcher J, Vercellotti GM, Penacho N, Seth P, Sukhatme V, Ahmed A, Pandolfi PP, Helczynski L, Bjartell A, Persson JL, Otterbein LE. Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. Cancer Res. 2013 Dec 01; 73(23):7009-21. PMID: 24121491.
    Citations: 68     Fields:    Translation:HumansAnimalsCells
  36. Husain Z, Seth P, Sukhatme VP. Tumor-derived lactate and myeloid-derived suppressor cells: Linking metabolism to cancer immunology. Oncoimmunology. 2013 Nov 01; 2(11):e26383. PMID: 24404426.
    Citations: 29     
  37. Chan B, Sukhatme VP. One-step purification of soluble recombinant human 6-phosphogluconate dehydrogenase from Escherichia coli. Protein Expr Purif. 2013 Nov; 92(1):62-6. PMID: 24018234.
    Citations:    Fields:    Translation:HumansCells
  38. Chan B, VanderLaan PA, Sukhatme VP. 6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met. Biochem Biophys Res Commun. 2013 Sep 20; 439(2):247-51. PMID: 23973484.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  39. Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol. 2013 Aug 01; 191(3):1486-95. PMID: 23817426.
    Citations: 153     Fields:    Translation:HumansAnimalsCells
  40. Hanai JI, Doro N, Seth P, Sukhatme VP. ATP citrate lyase knockdown impacts cancer stem cells in vitro. Cell Death Dis. 2013 Jun 27; 4:e696. PMID: 23807225.
    Citations: 34     Fields:    Translation:HumansCells
  41. Cerdeira AS, Rajakumar A, Royle CM, Lo A, Husain Z, Thadhani RI, Sukhatme VP, Karumanchi SA, Kopcow HD. Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors. J Immunol. 2013 Apr 15; 190(8):3939-48. PMID: 23487420.
    Citations: 52     Fields:    Translation:HumansCells
  42. Arnaout R, Buck TP, Roulette P, Sukhatme VP. Predicting the cost and pace of pharmacogenomic advances: an evidence-based study. Clin Chem. 2013 Apr; 59(4):649-57. PMID: 23230323.
    Citations: 5     Fields:    
  43. Sun X, Han L, Seth P, Bian S, Li L, Csizmadia E, Junger WG, Schmelzle M, Usheva A, Tapper EB, Baffy G, Sukhatme VP, Wu Y, Robson SC. Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice. Hepatology. 2013 Jan; 57(1):205-16. PMID: 22859060.
    Citations: 36     Fields:    Translation:AnimalsCells
  44. Retsky M, Demicheli R, Hrushesky WJ, Forget P, De Kock M, Gukas I, Rogers RA, Baum M, Sukhatme V, Vaidya JS. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. Curr Med Chem. 2013; 20(33):4163-76. PMID: 23992307.
    Citations: 31     Fields:    Translation:Humans
  45. Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, van't Veer LJ, Spellman PT, Gray JW. Modeling precision treatment of breast cancer. Genome Biol. 2013; 14(10):R110. PMID: 24176112.
    Citations: 115     Fields:    Translation:HumansCells
  46. Sukhatme VP, Chan B. Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescence. FEBS Lett. 2012 Jul 30; 586(16):2389-95. PMID: 22677172.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  47. Hanai J, Doro N, Sasaki AT, Kobayashi S, Cantley LC, Seth P, Sukhatme VP. Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J Cell Physiol. 2012 Apr; 227(4):1709-20. PMID: 21688263.
    Citations: 42     Fields:    Translation:HumansAnimalsCells
  48. Wagner BK, Gilbert TJ, Hanai J, Imamura S, Bodycombe NE, Bon RS, Waldmann H, Clemons PA, Sukhatme VP, Mootha VK. A small-molecule screening strategy to identify suppressors of statin myopathy. ACS Chem Biol. 2011 Sep 16; 6(9):900-4. PMID: 21732624.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  49. Bhatt RS, Zurita AJ, O'Neill A, Norden-Zfoni A, Zhang L, Wu HK, Wen PY, George D, Sukhatme VP, Atkins MB, Heymach JV. Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. Br J Cancer. 2011 Jun 28; 105(1):112-7. PMID: 21673679.
    Citations: 9     Fields:    Translation:HumansCells
  50. Seth P, Grant A, Tang J, Vinogradov E, Wang X, Lenkinski R, Sukhatme VP. On-target inhibition of tumor fermentative glycolysis as visualized by hyperpolarized pyruvate. Neoplasia. 2011 Jan; 13(1):60-71. PMID: 21245941.
    Citations: 49     Fields:    Translation:HumansAnimalsCells
  51. Ren JG, Seth P, Everett P, Clish CB, Sukhatme VP. Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2. PLoS One. 2010 Sep 02; 5(9). PMID: 20824065.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  52. Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V, Heymach JV, Atkins MB, McDermott D, Sukhatme VP. A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer. 2010 Apr 01; 116(7):1751-6. PMID: 20120033.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  53. Boguski MS, Mandl KD, Sukhatme VP. Drug discovery. Repurposing with a difference. Science. 2009 Jun 12; 324(5933):1394-5. PMID: 19520944.
    Citations: 51     Fields:    Translation:Humans
  54. Cao P, Hanai J, Tanksale P, Imamura S, Sukhatme VP, Lecker SH. Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect. FASEB J. 2009 Sep; 23(9):2844-54. PMID: 19406843.
    Citations: 29     Fields:    Translation:AnimalsCells
  55. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, Sukhatme VP, Seth P. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. . 2009 Mar; 8(3):626-35. PMID: 19276158.
    Citations: 103     Translation:HumansAnimalsCells
  56. Chan B, Sukhatme VP. Suppression of Tie-1 in endothelial cells in vitro induces a change in the genome-wide expression profile reflecting an inflammatory function. FEBS Lett. 2009 Mar 18; 583(6):1023-8. PMID: 19236867.
    Citations: 12     Fields:    Translation:HumansCells
  57. Chan B, Sukhatme VP. Receptor tyrosine kinase EphA2 mediates thrombin-induced upregulation of ICAM-1 in endothelial cells in vitro. Thromb Res. 2009 Mar; 123(5):745-52. PMID: 18768213.
    Citations: 19     Fields:    Translation:HumansCells
  58. Wei F, Karihaloo A, Yu Z, Marlier A, Seth P, Shibazaki S, Wang T, Sukhatme VP, Somlo S, Cantley LG. Neutrophil gelatinase-associated lipocalin suppresses cyst growth by Pkd1 null cells in vitro and in vivo. Kidney Int. 2008 Nov; 74(10):1310-1318. PMID: 18974761.
    Citations: 22     Fields:    Translation:AnimalsCells
  59. Gallagher DC, Parikh SM, Balonov K, Miller A, Gautam S, Talmor D, Sukhatme VP. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock. 2008 Jun; 29(6):656-61. PMID: 18091573.
    Citations: 58     Fields:    Translation:HumansCells
  60. Chan B, Yuan HT, Ananth Karumanchi S, Sukhatme VP. Receptor tyrosine kinase Tie-1 overexpression in endothelial cells upregulates adhesion molecules. Biochem Biophys Res Commun. 2008 Jul 04; 371(3):475-9. PMID: 18448073.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  61. Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, Bubley GJ. Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU Int. 2008 Aug; 102(3):358-63. PMID: 18394010.
    Citations: 9     Fields:    Translation:HumansCells
  62. Zeidel M, Bonventre J, Forrest J, Sukhatme V. A national course for renal fellows: the origins of renal physiology. J Am Soc Nephrol. 2008 Apr; 19(4):649-50. PMID: 18322157.
    Citations: 3     Fields:    
  63. Hanai J, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J, Kishi S, Yamashita M, Phillips PS, Sukhatme VP, Lecker SH. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest. 2007 Dec; 117(12):3940-51. PMID: 17992259.
    Citations: 89     Fields:    Translation:HumansAnimalsCells
  64. Giuliano JS, Lahni PM, Harmon K, Wong HR, Doughty LA, Carcillo JA, Zingarelli B, Sukhatme VP, Parikh SM, Wheeler DS. Admission angiopoietin levels in children with septic shock. Shock. 2007 Dec; 28(6):650-654. PMID: 18092380.
    Citations: 60     Fields:    Translation:Humans
  65. Hakimé A, Hines-Peralta A, Peddi H, Atkins MB, Sukhatme VP, Signoretti S, Regan M, Goldberg SN. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology. 2007 Aug; 244(2):464-70. PMID: 17641366.
    Citations: 26     Fields:    Translation:Animals
  66. Mammoto T, Parikh SM, Mammoto A, Gallagher D, Chan B, Mostoslavsky G, Ingber DE, Sukhatme VP. Angiopoietin-1 requires p190 RhoGAP to protect against vascular leakage in vivo. J Biol Chem. 2007 Aug 17; 282(33):23910-8. PMID: 17562701.
    Citations: 76     Fields:    Translation:HumansAnimalsCells
  67. Yuan HT, Venkatesha S, Chan B, Deutsch U, Mammoto T, Sukhatme VP, Woolf AS, Karumanchi SA. Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival. FASEB J. 2007 Oct; 21(12):3171-83. PMID: 17504972.
    Citations: 42     Fields:    Translation:HumansAnimalsCells
  68. Gallagher DC, Bhatt RS, Parikh SM, Patel P, Seery V, McDermott DF, Atkins MB, Sukhatme VP. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin Cancer Res. 2007 Apr 01; 13(7):2115-20. PMID: 17404094.
    Citations: 22     Fields:    Translation:HumansCells
  69. Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):667s-670s. PMID: 17255291.
    Citations: 16     Fields:    Translation:Humans
  70. Bhatt RS, Seth P, Sukhatme VP. Biomarkers for monitoring antiangiogenic therapy. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):777s-780s. PMID: 17255309.
    Citations: 9     Fields:    Translation:Humans
  71. Venkatesha S, Hanai J, Seth P, Karumanchi SA, Sukhatme VP. Lipocalin 2 antagonizes the proangiogenic action of ras in transformed cells. Mol Cancer Res. 2006 Nov; 4(11):821-9. PMID: 17114340.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  72. Mochida Y, Parisuthiman D, Kaku M, Hanai J, Sukhatme VP, Yamauchi M. Nephrocan, a novel member of the small leucine-rich repeat protein family, is an inhibitor of transforming growth factor-beta signaling. J Biol Chem. 2006 Nov 24; 281(47):36044-51. PMID: 16990280.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  73. Hu G, Tang J, Zhang B, Lin Y, Hanai J, Galloway J, Bedell V, Bahary N, Han Z, Ramchandran R, Thisse B, Thisse C, Zon LI, Sukhatme VP. A novel endothelial-specific heat shock protein HspA12B is required in both zebrafish development and endothelial functions in vitro. J Cell Sci. 2006 Oct 01; 119(Pt 19):4117-26. PMID: 16968741.
    Citations: 23     Fields:    Translation:HumansAnimalsCells
  74. McDermott DF, Cho DC, Merchan JR, Bhatt RS, Seery V, Mosher JL, Farquhar MB, Mier JW, Atkins MB, Sukhatme VP. A phase II pilot trial of low dose, continuous infusion, or "metronomic", paclitaxel and oral celecoxib in patients with metastatic melanoma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):8010. PMID: 27955581.
  75. Merchan JR, Tang J, Hu G, Lin Y, Mutter W, Tong C, Karumanchi SA, Russell SJ, Sukhatme VP. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J Natl Cancer Inst. 2006 Jun 07; 98(11):756-64. PMID: 16757700.
    Citations: 6     Fields:    Translation:AnimalsCells
  76. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006 Jun; 12(6):642-9. PMID: 16751767.
    Citations: 493     Fields:    Translation:HumansAnimalsCells
  77. Hines-Peralta A, Sukhatme V, Regan M, Signoretti S, Liu ZJ, Goldberg SN. Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. Radiology. 2006 Jul; 240(1):82-9. PMID: 16720872.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  78. Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol. 2006 Apr; 17(4):1112-27. PMID: 16565259.
    Citations: 125     Fields:    Translation:Humans
  79. Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, Karumanchi SA, Sukhatme VP. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med. 2006 Mar; 3(3):e46. PMID: 16417407.
    Citations: 197     Fields:    Translation:HumansAnimalsCells
  80. Tang J, Hu G, Hanai J, Yadlapalli G, Lin Y, Zhang B, Galloway J, Bahary N, Sinha S, Thisse B, Thisse C, Jin JP, Zon LI, Sukhatme VP. A critical role for calponin 2 in vascular development. J Biol Chem. 2006 Mar 10; 281(10):6664-72. PMID: 16317011.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  81. Seth P, Lin Y, Hanai J, Shivalingappa V, Duyao MP, Sukhatme VP. Magic roundabout, a tumor endothelial marker: expression and signaling. Biochem Biophys Res Commun. 2005 Jul 01; 332(2):533-41. PMID: 15894287.
    Citations: 47     Fields:    Translation:HumansCells
  82. Karumanchi SA, Maynard SE, Stillman IE, Epstein FH, Sukhatme VP. Preeclampsia: a renal perspective. Kidney Int. 2005 Jun; 67(6):2101-13. PMID: 15882253.
    Citations: 69     Fields:    Translation:Humans
  83. Bedell VM, Yeo SY, Park KW, Chung J, Seth P, Shivalingappa V, Zhao J, Obara T, Sukhatme VP, Drummond IA, Li DY, Ramchandran R. roundabout4 is essential for angiogenesis in vivo. Proc Natl Acad Sci U S A. 2005 May 03; 102(18):6373-8. PMID: 15849270.
    Citations: 81     Fields:    Translation:AnimalsCells
  84. Zacharski LR, Sukhatme VP. Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer? J Thromb Haemost. 2005 Mar; 3(3):424-7. PMID: 15748226.
    Citations: 18     Fields:    Translation:Humans
  85. Hanai J, Mammoto T, Seth P, Mori K, Karumanchi SA, Barasch J, Sukhatme VP. Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem. 2005 Apr 08; 280(14):13641-7. PMID: 15691834.
    Citations: 42     Fields:    Translation:HumansAnimalsCells
  86. Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP. Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer. 2005 Jan 20; 113(3):490-8. PMID: 15455390.
    Citations: 31     Fields:    Translation:HumansCellsCTClinical Trials
  87. Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, Blink AL, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Urinary placental growth factor and risk of preeclampsia. JAMA. 2005 Jan 05; 293(1):77-85. PMID: 15632339.
    Citations: 75     Fields:    Translation:Humans
  88. Chan B, Sinha S, Cho D, Ramchandran R, Sukhatme VP. Critical roles of CD146 in zebrafish vascular development. Dev Dyn. 2005 Jan; 232(1):232-44. PMID: 15580611.
    Citations: 19     Fields:    Translation:AnimalsCells
  89. Kale S, Hanai J, Chan B, Karihaloo A, Grotendorst G, Cantley L, Sukhatme VP. Microarray analysis of in vitro pericyte differentiation reveals an angiogenic program of gene expression. FASEB J. 2005 Feb; 19(2):270-1. PMID: 15579670.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  90. Wolf M, Hubel CA, Lam C, Sampson M, Ecker JL, Ness RB, Rajakumar A, Daftary A, Shakir AS, Seely EW, Roberts JM, Sukhatme VP, Karumanchi SA, Thadhani R. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab. 2004 Dec; 89(12):6239-43. PMID: 15579783.
    Citations: 44     Fields:    Translation:Humans
  91. Bdolah Y, Sukhatme VP, Karumanchi SA. Angiogenic imbalance in the pathophysiology of preeclampsia: newer insights. Semin Nephrol. 2004 Nov; 24(6):548-56. PMID: 15529289.
    Citations: 17     Fields:    Translation:Humans
  92. Thadhani R, Ecker JL, Mutter WP, Wolf M, Smirnakis KV, Sukhatme VP, Levine RJ, Karumanchi SA. Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. Hypertension. 2004 May; 43(5):988-92. PMID: 15023932.
    Citations: 22     Fields:    Translation:Humans
  93. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004 Feb 12; 350(7):672-83. PMID: 14764923.
    Citations: 762     Fields:    Translation:Humans
  94. Feinberg MW, Watanabe M, Lebedeva MA, Depina AS, Hanai J, Mammoto T, Frederick JP, Wang XF, Sukhatme VP, Jain MK. Transforming growth factor-beta1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J Biol Chem. 2004 Apr 16; 279(16):16388-93. PMID: 14754879.
    Citations: 15     Fields:    Translation:AnimalsCells
  95. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004 Feb; 89(2):770-5. PMID: 14764795.
    Citations: 103     Fields:    Translation:Humans
  96. Chan B, Merchan JR, Kale S, Sukhatme VP. Antiangiogenic property of human thrombin. Microvasc Res. 2003 Jul; 66(1):1-14. PMID: 12826069.
    Citations: 6     Fields:    Translation:HumansCells
  97. McDonald GA, Sarkar P, Rennke H, Unemori E, Kalluri R, Sukhatme VP. Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo. Am J Physiol Renal Physiol. 2003 Jul; 285(1):F59-67. PMID: 12820641.
    Citations: 20     Fields:    Translation:AnimalsCells
  98. Merchan JR, Chan B, Kale S, Schnipper LE, Sukhatme VP. In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J Natl Cancer Inst. 2003 Mar 05; 95(5):388-99. PMID: 12618504.
    Citations: 16     Fields:    Translation:Humans